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Abstract: Nephrogenic systemic fibrosis is a chronic, progressive condition that develops in some patients with
renal impairment after exposure to gadolinium-based contrast agents used in magnetic resonance imaging.
Thickening of the skin is typical, usually affecting the extremities. Visceral organs can also be affected. The diag-
nosis of the disease requires careful clinicopathological correlation. Treatment aims at restoring renal function,
which is associated with delayed progression and, eventually, remission of skin changes. Reduction and preven-
tion of nephrogenic systemic fibrosis cases are based on limiting the use of gadolinium-based contrast agents in
patients with kidney disorders (especially in patients with advanced renal failure at stages 4 and 5), and restric-
ting their use to situations in which they are essential to diagnosis/follow-up. Other than limiting exposure to
gadolinium based contrast agents, no effective preventive methods have been reported. Due to increased aware-
ness about the disease among radiologists and nephrologists, the incidence of nephrogenic systemic fibrosis is
declining.
Keywords: Contrast media; Gadolinium; Magnetic resonance imaging; Nephrogenic fibrosing dermopathy; Renal
insufficiency
Resumo: Fibrose nefrogênica sistêmica é condição crônica, progressiva, desenvolvida caracteristicamente em
pacientes nefropatas após exposição a contrastes radiológicos que contenham gadolínio. O espessamento cutâ-
neo é aspecto típico, envolvendo predominantemente as extremidades. Envolvimento visceral pode ocorrer. O
diagnóstico da doença requer cuidadosa correlação clínico-patológica. O tratamento visa à restauração da função
renal, que se associa ao retardo da progressão e, eventualmente, remissão das alterações cutâneas. A prevenção
da ocorrência e redução da incidência baseiam-se na limitação do uso de contrastes à base de gadolínio em nefro-
patas (especialmente na insuficiência renal avançada em estágios 4 e 5), restringindo-os às condições nas quais
seja imprescindível ao diagnóstico/acompanhamento. À exceção da restrição de exposição aos agentes de con-
traste a base de gadolínio, não há métodos preventivos efetivos relatados. Devido à ampla divulgação da doença
entre radiologistas e nefrologistas, a incidência da fibrose nefrogênica sistêmica está em declínio. 
Palavras-chave: Dermopatia fibrosante nefrogênica; Gadolínio; Imagem por ressonância magnética; Insuficiência
renal; Meios de contraste 
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Gadolinium (Gd) is a rare lanthanide metal pre-
sent in contrast media used to perform magnetic reso-
nance imaging (MRI).4,12 The association between the
use of GBCA and the development of NSF was first
suggested in 2006 by Grobner16 in Austria and
Marckman et al. in Denmark.17
The usual dose of Gd is 0.1 mmol/kg, but it is
higher for magnetic resonance angiography examina-
tions, which pose a greater risk of developing NSF. Its
toxic ionic form (Gd3+) is administered in combina-
tion with larger organic molecules - chelates - forming
stable complexes.4 These complexes are rapidly excre-
ted in individuals with normal renal function, and
their use is considered safe in these cases. If Gd3+ dis-
sociates from its ligand, it binds with plasma phospha-
te and forms insoluble molecules. After abnormal vas-
cular extravasation, precipitated phosphate salts may
deposit in the interstitium and be phagocytized by
macrophages, producing profibrotic cytokines. Other
increased anions in renal insufficiency may also preci-
pitate Gd3+.2
The mechanisms through which injury is cau-
sed in the skin and other organs are not well unders-
tood.12,16,17-19 The discovery of Gd deposits in the skin of
affected patients12 led to the recommendation of cau-
tious use of these contrast agents in patients with CRI
by the Food and Drug Administration (FDA) and the
European Medicines Agency (EMA).
In individuals with normal renal function, gado-
linium based contrast agents have half-life of 2
hours.12 GBCA are eliminated by glomerular filtra-
tion, without contribution of tubular secretion and its
renal clearance ranges from 1.1 to 1.6 ml/kg/min.
Over 95% of the injected dose is eliminated within 24
hours and less than 3% in the feces.4 Since clearance
is almost exclusively renal, GBCA elimination time is
prolonged in patients with renal impairment.20
Clearance of the contrast agent in anuric patients is
performed exclusively by dialysis.6,10 About 93% of Gd
is removed after two consecutive sessions of hemodia-
lysis,12 but this number is significantly lower when it
comes to peritoneal dialysis, which clears about 75%
of the lanthanide after 5 days. This difference is due to
the relatively low molecular weight, low volume of
distribution and low protein-binding characteristics of
the complexes with Gd.21 The pharmacokinetic profile
of Gd in healthy individuals and in individuals with
renal impairment is showed in table 1. 20
A study by Joffe et al. showed low peritoneal
INTRODUCTION
Nephrogenic systemic fibrosis (NSF) was first
recognized in 1997 and described in 2000 by Cowper
et al1 as a scleromyxedema-like illness in patients with
chronic renal insufficiency (CRI) on renal replace-
ment therapy, being characterized as progressive cuta-
neous fibrosis. At that time, only the skin was thought
to be involved in the disease, which was called neph-
rogenic fibrosing dermopathy. Later, multisystem
organ involvement (lung, liver, muscles- including the
myocardium) was described, and the nomenclature
was changed to NSF.
To date, all reports have been described in
patients with acute or chronic renal insufficiency.1-8
Association with prior exposure to gadolinium-based
contrast agents (GBCA) was first reported in 2006.
Patients on renal replacement therapy are believed to
be at greater risk of developing NSF when on perito-
neal dialysis compared to hemodialysis.2,9
The typical clinical symptom is hardening of the
skin, generally of the extremities but sometimes
extending to the trunk. There is associated brawny
hyperpigmentation, frequently accompanied by sen-
sory symptoms. Joint contractures are common, and
frequently lead to impaired mobility. Laboratory may
be helpful to exclude the differential diagnosis of NSF.
An anatomopathological analysis should always be
performed to confirm diagnosis. There is no univer-
sally effective treatment, although patients early in
their course frequently show improvement following
a successful renal transplant. Prevention is mandatory
in patients at risk.
EPIDEMIOLOGY
NSF is a rare condition, with fewer than 500
cases reported in the literature.2,10,11 It has no predilec-
tion for gender or ethnicity, and it most often affects
middle-aged individuals, but there are reports of cases
occurring from childhood to senescence.2,4,10-13 Also,
there is no predilection for etiology or duration of
renal failure.4,8 A cohort study developed in the United
States of America in 2007 with patients on dialysis sho-
wed a 2.4% risk of developing the disease after expo-
sure to gadolinium-based contrast media of different
formulations.14 Patients on peritoneal dialysis appear
to be at greater risk than those on hemodialysis.4,15
The disease was described after the introduc-
tion of GBCA in high concentrations to perform mag-
netic resonance angiography in 1997 and after its use
in a significant number of patients with renal impair-
ment. At that time, the use of GBCA represented the
possibility of avoiding the use of iodinated contrast
media in patients who already had significant renal
function impairment. Moreover, the use of increasing
cumulative doses of gadolinium-based compounds
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clearance of Gd: 65% of the injected gadodiamide was
eliminated during a hemodialysis session, while 69%
was eliminated after 22 consecutive days of ambulato-
ry peritoneal dialysis.22 The authors reported that Gd
has a half-life of 34.3h in nondialyzed patients with
severe renal failure, which is reduced to 2.6h with
hemodialysis. Peritoneal dialysis was not effective in
the removal of Gd.
According to their structure, GBCA can be divi-
ded into macrocyclic and linear forms. In the first
category, Gd3+ is bound by several bonds to the inside
of a ring shaped chelate molecule, making its release
dependent on the simultaneous breaking of multiple
bonds. As this is thermodynamically unlikely, there is
greater protection against dechelation of the Gd ion.
As for charge, GBCA can be ionic and nonionic.4,11,23-26
GBCA include nine different proprietary formulations,
which are listed in chart 1. 4,12,24-26
Although several GBCA are used in European
countries, only two have been approved by the EMA
for use throughout the European Union:
Gadoversetamide (OptiMARK®) and Gadofosveset
(Vasovist®/Ablavar®). The latter was authorized in 2005
and unauthorized in 2011.26 The EMA classifies con-
trast agents into high risk (OptiMARK®, Omniscan®,
Magnevist®), medium risk (Vasovist®, Primovist®,
TABLE 1: Pharmacokinetic profile of Gd in healthy individuals and in individuals with moderate and 
severe renal failure
Group of patients T1/2 (hours) Renal clearance of Gd (ml/min)
Healthy individuals with normal renal function 2.0 118
Moderate renal failure (CrCl 31-60 ml/min) 5.6 47
Severe renal failure (CrCl 10-30 ml/min) 9.2 22
T1/2: half-life, CrCl: creatinine clearance
CHART 1: Gd chelates used for Magnetic Resonance Imaging
Agent Trade name Molecular Charge Elimination Approval
Structure
Gadopentetate dimeglumine Magnevist Linear Ionic Renal FDA (1988)
Magnevistan ANVISA 
Gadoteridol ProHance Cyclic Nonionic Renal FDA (1992)
ANVISA
Gadodiamide Omniscan Linear Nonionic Renal FDA (1993)
ANVISA
Gadoversetamide OptiMARK Linear Nonionic Renal FDA (1999)
EMA (2007)
ANVISA
Gadobenate dimeglumine MultiHance Linear Ionic 97% Renal FDA (2004)
3% Bile
Gadoxetate disodium Eovist Linear Ionic 50% Renal FDA (2008)
Primovist 50% Bile
Gadofosveset Ablavar Linear Ionic 91% Renal FDA (2008)
9% Bile
Gadobutrol Gadovist Cyclic Nonionic Renal ANVISA
Gadoteric acid Dotarem Cyclic Ionic Renal ANVISA
FDA: Food and Drug Administration, EMA: European Medicines Agency, ANVISA: National Health Surveillance Agency
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MultiHance®) and low risk (Dotarem®, ProHance® e
Gadovist®).
It has been shown in murine models that depo-
sition of Gd is greater in tissues when nonionic linear
agents (gadodiamide) are used, followed by the use of
ionic linear agents and, finally, macrocyclic agents.27
However, the risk of developing NSF with different
GBCA has not yet been determined. Previous use of
gadodiamide has been reported in most cases.12 The
molecular structure and stability of the chelate seem
to be involved in the development of NSF.24
After 15 days of incubation in human serum,
nonionic linear agents show in vitro release of Gd 10
times higher when compared with ionic linear agents.
Elevated serum phosphate accelerates the release of
Gd3+ from nonionic linear agents and, to a lesser
extent, from ionic linear agents. Macrocyclic agents
are the most stable in vitro, in media with normal or
high phosphate concentrations.28
A retrospective study covering a period of 8
years (1999 - 2007) with data from 94,917 patients
exposed to Gd showed a mean dose of 54ml of con-
trast agent in patients who developed histologically
proven NSF. Gadodiamide was the contrast agent
used in 69.3% of all exposures.5 An association bet-
ween higher cumulative dose of GBCA and develop-
ment of NSF has not yet been proved, although some
data do seem to suggest it.
New contrast agents show utilizing a hepatobi-
liary clearance route may be as effective as those using
exclusively renal elimination. If a route is impaired,
the other becomes responsible for eliminating a grea-
ter fraction of GBCA. Despite the scarcity of cases
reported in relation to these newer contrast agents,
one cannot discard their potential to trigger NSF,
given their lower frequency of use, predominant use
in patients with liver disease and the knowledge that
radiologists had about NSF when these new agents
were launched. According to the FDA, there is no con-
trast agent considered completely safe for use in
patients with renal impairment.
NSF risk stratification based on the pharmaco-
logical properties of GBCA represents an attractive
hypothesis, however, it has not yet been proven.
Focusing on chemical aspects leads to neglect of other
important considerations in the context of NSF.
Chronic Renal Insufficiency (CRI) 
To date, all reported cases of NSF were develo-
ped by individuals with impaired renal func-
tion.2,5,7,10,12,25 Most cases occur in patients with CRI
(stages 4 and 5), patients on renal replacement thera-
py (hemodialysis and peritoneal dialysis) and kidney
transplant recipients.25,29 However, NSF can also deve-
lop after exposure to GBCA in cases of acute kidney
injury. No predisposing relationship has been proven
between time of renal dysfunction, its etiology and
type of replacement therapy and the development of
NSF.10,12
CRI is classified into five stages, according to
the estimated glomerular filtration rate (eGFR) (Table
2). Although most cases have been reported in
patients with eGFR <15ml/min/1.73m², triggering
eGFR has not been established for the disease.12
ETIOPATHOGENIC MECHANISMS
The sequence of physiopathological events in
NSF is not yet clear.4,5 Theories postulate that NSF
results from activation of circulating fibrocytes, a
population of bone marrow-derived circulating
mesenchymal stem cells, that are induced by Gd to
differentiate in the dermis into cells that functionally
and histologically resemble dermal fibroblasts.
Dermal fibroblasts of skin affected by NSF produce
greater amounts of sulfated glycosaminoglycans when
compared with fibroblasts of normal skin. It is still
unclear which type of fibroblasts contributes to the
development of NSF. Cowper and Bucala believe that
it is the circulating fibrocytes, since the cells seen in
tissues show expression of CD34 and procollagen 1.30 
The abnormal local enviroment may disrupt the
normal process of fibrocytes maturation. Even though
circulating fibrocytes recruitment suggests that NSF is
a systemic disease, recent findings point that GBCA
may also act locally, leading to inflammation and fibro-
sis of the tissues. 18
Direct toxic effects are suggested by the presen-
ce of Gd deposits in the skin of individuals who deve-
lop NSF.12,31,32 In its free form, Gd interacts with extra-
cellular phosphates to produce insoluble gadolinium
phosphate, which is subsequently phagocytosed by
tissue macrophages. These macrophages are presu-
med to produce pro-fibrotic cytokines that promote
the migration of additional machophages and fibrocy-
tes.2,4,6 Fibrosis results from the binding of these pro-
CRI Estimated Glomerular 
Filtration Rate
Stage 0* ≥ 90ml/min/1.73m2
Stage 1** ≥ 90ml/min/1.73m²
Stage 2 60 - 89ml/min/1.73m²
Stage 3 30 - 59ml/min/1.73m²
Stage 4 15 - 29ml/min/1.73m²
Stage 5 *** <15ml/min/1.73m2
* Risk groups for CRI in the absence of renal impairment.
** Renal impairment with normal or increased eGFR .
*** Or renal impairment requiring permanent dialysis.
TABLE 2: Stages of CRI
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fibrotic cytokines with their receptors on fibrocytes,
stimulating extracellular matrix proteins and collagen
synthesis. The initial cutaneous infiltrate containing
CD68/factor XIIIa-positive dendritic cells could repre-
sent a possible host response to noxious stimuli.4
An increase in serum iron (Fe) concentration
can induce in vivo transmetallation of Gd, a pheno-
menon whereby free Gd is released from the chelate
and subsequent binds to endogenous ions. Treatment
with exogenous Fe and a chronic microinflammation
state in CRI may contribute to the release of free
Gd.19,33 The combination of free Gd and the toxic
effects of Fe can result in initial tissue damage, espe-
cially in situations of inflammation and oxidative
stress in patients with CRI. The underlying inflamma-
tion may facilitate profibrotic cytokines and chemoki-
nes synthesis.25
Erythropoietin (EPO), due to its fibrogenic pro-
perties,4 has been theorized to play a triggering or faci-
litating role in the pathogenesis of NSF in patients
with CRI.2,10 Since advanced renal dysfunction leads to
insufficient endogenous production of EPO, patients
on renal replacement therapy often use recombinant
human EPO to maintain their red blood cell count. It
is postulated that the ability of EPO to stimulate mar-
row cell lines may also provoke the secondary stimu-
lation of fibrocyte production.4,34,35 A case-matched
study of patients with NSF by the Centers for Disease
Control did not identify EPO use as a significant risk
factor for the development of NSF, however.15
Increased expression and activation of transglu-
taminases in NSF were documented, but with no exact
role in the pathogenesis of the disease.2 Some patients
present chronic liver disease, including hepatitis B or
C.36-38 Associations between hepatorenal syndrome
and post liver transplantation period with develop-
ment of NSF have been reported,39 although there is
no greater risk in this clinical scenario than that attri-
buted to renal failure alone.
If compared to other conditions that affect
chronically nephropathic patients, NSF is considered
to be rare. According to this, other patient’s features
may be required to the development of the fibrosing
condition further than the exposition to GBCA.
Vascular injuries and proinflammatory state are
important risk factors to NSF onset.25 Until now no
responsible etiopathogenic factors nor their specific
roles have been defined.
Procoagulant states, recent surgery (especially
vascular), deep vein thrombosis,6,9,40,41 newly transplan-
ted-kidney failure and sudden-onset kidney disease
with significant swelling of the extremities may be
associated with NSF. The injured vessels allow the dis-
sociated Gd prompt penetration in the interstitial
space and tissues.25 Surgery and thrombotic events fre-
quently occur two weeks before the onset of cuta-
neous manifestations.10 Metabolic acidosis has also
been associated with NSF, 2 but has been repeatedly
refuted as an independent risk factor. Both endothe-
lial damage and hypercoagulability facilitate the
migration of blood fibrocytes.10 Chart 2 summarizes
the risk factors for developing NSF after use of GBCA.
CLINICAL MANIFESTATIONS
Cutaneous changes develop days to weeks after
exposure to GBCA. They are characterized by thicke-
ning and hardening of the skin associated with braw-
ny hyperpigmentation, typically presenting in a sym-
metric fashion.1,42 These changes initially affect the dis-
tal portion of the lower limbs,2 progressing proximal-
ly, sometimes reaching the trunk. Involvement of the
lower limbs typically begins with the talocalcaneal
joints, ascending to the central region of the thighs. As
for involvement of the upper limbs, the changes ini-
tially occur on the wrists, also with ascendant progres-
sion to the arms.12 The face is typically not affected.
There have been reports of edema and blisters on
hands and feet.2 A rapidly progressive course is seen in
5% of the cases.10
The lesions may be pruritic, painful or present
a local burning sensation. The initial manifestation
may be a pruritic erythematous rash after exposure to
the contrast agent. In many cases, there is edema of
the affected areas before the appearance of the charac-
teristic woody textures.4 Erythematous to hyperpig-
mented thickened plaques with an amoeboid aspect
appear (Figure 1). Hypopigmented, erythematous or
normochromic macules and papules may coalesce,
forming plaques. The plaques may have a cobblestone
appearance. The skin gradually becomes fibrotic and
adherent to the underlying fascia, in a diffuse or linear
fashion, with a woody consistency to palpation
(Figure 2).12 It acquires a shiny aspect with perifollicu-
lar depressions, with a peau d’orange texture. Soft tis-
sue calcifications are eventually revealed by radio-
graphs.10
There might be joint motion restriction secon-
dary to skin involvement. Joint contractures and
motion restrictions may develop within days or weeks,
leading to progressive limitation of daily activities and
reduced patient’s quality of life.12 The involvement of
CRI stages 4 to 5 Vascular surgical procedures
Thrombotic events Endothelial damage
Transplanted kidney failure Hypercoagulability
Sudden-onset kidney disease
CHART 2: Hypothesized risk factors for NSF after 
use of GBCA
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tendons and periarticular tissues (without inflamma-
tion) also contributes to restriction of mobility.
Extracutaneous manifestations may occur, and
no predictive factors have been identified so far.
Telangiectasia and scleral plaques have been reported,
but without visual acuity changes.2,42 Visceral and ske-
letal muscles may be affected. Gd deposition in the
cardiac tissue can be as high as in the affected skin,43
which can lead to myocardial fibrosis.4 Fibrosis of
serous membranes, including the meninges, may also
occur.9,40,41 Systemic involvement may, therefore, lead
to heart disease, pulmonary hypertension and muscle
weakness. Fluctuating hypertension has been descri-
bed prior to the development of cutaneous chan-
ges.2,10 As the disease progresses, hypotension and
thromboembolic events may occur. Sensory-motor
neuropathy occurs as a manifestation of peripheral
nerve involvement.
Visceral involvement may be seen in patients
with extensive skin disease.4 The prognosis varies
depending on the severity of the systemic involve-
ment, extent of skin lesions and time of onset.
DIAGNOSIS
To date, there are no laboratory and pathogno-
monic histopathological findings or findings consis-
tently associated with the disease that allow its diag-
nosis in isolation. The diagnosis must be established
by a correlation between clinical, laboratory and histo-
pathological findings. The presence of fibrotic skin
changes in a patient with renal impairment should
prompt further investigation.
The diagnosis is confirmed by anatomopatholo-
gical examination and the findings vary according to
the stage of evolution of the disease. As a rule, the epi-
dermis is unaltered. The dermis shows increased
deposition of collagen and mucin. Initially, deposits of
mucin are prominent, separated by thin collagen bun-
dles. With the advance of the disease, these collagen
bundles thicken and are separated by clefts (Figure 3).
There is no significant inflammation. In advanced sta-
ges, thick collagen bundles are separated by less pro-
minent clefts, fibroblasts and elastic fibers. Clefts are
present in all stages of the disease. The fibrotic pro-
cess may extend to the subcutaneous tissue, widening
the interlobular septa and yielding a microlobular
architecture (Figure 4).2 Therefore, samples for biopsy
should be of adequate depth and volume.
Fibrocytes - bone marrow-derived mesenchy-
mal spindle cells - positive for CD34, procollagen 1
and vimentin, are found distributed between the col-
lagen bundles, generally parallel to their predominant
direction.2,6 Recent lesions (within the first 20 weeks)
show a great number of these cells in the reticular der-
mis in an interconnected manner.42 As the disease pro-
gresses, the expression of procollagen 1 by fibrocytes
increases, correlating with the extracellular deposi-
tion of collagen.6 Old lesions (over 20 weeks) show
smaller mucin deposits, fewer fibroblasts and less pro-
minent clefts.42 However, increasing numbers of fibro-
blasts and macrophages have been described with the
progression of skin fibrosis.6 The precise role of fibro-
cytes in the etiopathogenesis of the disease is unclear.
It is not known whether they trigger the fibrotic pro-
cess (due to their ability to migrate to and enter dama-
ged tissues) or simply maintain the development of
fibrotic lesions.
Factor XIIIa-positive dendritic cells associated
with CD68-positive histiocytes, mono-and multinu-
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sed number of dendritic cells, with co-expression of
CD68 and factor XIIIa, has been shown in recent
lesions of NSF.2,12
Deposition of mucin, collagen and elastic fibers
can be seen in specific staining - Alcian blue or colloi-
dal iron, Verhoeff-van Gieson and Masson’s trichrome,
respectively. There are reports of calcification in and
around collagen bundles and elastic fibers, as well as
around the basement membrane of vessel walls and
histiocytes.2
Similar histopathological changes are observed
in the muscles underlying the affected areas. This
does not occur in areas of healthy skin. Muscular
involvement is associated with the extent of systemic
involvement.
The presence of Gd deposits can be seen via
spectrometry, but their intensity does not correlate
with the extent of clinical involvement. The degree of
fibrosis noted histopathologically does correlate with
the local concentration of deposited Gd.44,45
Therefore, the significance Gd deposition is unclear
to diagnosis and prognosis, and is not a necessary fin-
ding to render a diagnosis of NSF.2,6 The concentration
of Gd in the tissues of patients with NSF is 35 to 150
times higher than in normal individuals exposed to
Gd.25,44 Perivascular deposits of Gd and Fe have also
been demonstrated.46
Girardi et al. proposed major and minor clini-
cal and histopathological criteria for the diagnosis of
NSF.7 In their model, the demonstration and quantifi-
cation of Gd deposits are not required for diagnosis.
This definition of NSF was developed at Yale
University as part of the International NSF Registry,
and is based on nearly 400 cases in that collection.
The study authors comprised a multidisciplinary clini-
cal team with extensive experience with NSF. Further
studies are needed to confirm clinical applicability
and accuracy.
Positive serology for hepatitis B and C, eosinop-
hilia, presence of antinuclear antibodies, anticardioli-
pin antibodies and/or antiphospholipid antibodies, as
well as hypercoagulable state and alteration of inflam-
matory function tests are frequent laboratory findings.
Increase in serum calcium and phosphate concentra-
tions may also occur.12 However, among laboratory
tests, changes resulting from loss of renal function are
invariably found.
Due to the absence of pathognomonic findings,
diagnosis is based on the presence of typical clinical
manifestations in patients with renal impairment with
compatible histopathological symptoms. The non-spe-
cificity of imaging findings for both the diagnosis and
follow-up of patients with NSF restricts its use.
DIFFERENTIAL DIAGNOSIS
The differential diagnosis of NSF includes other
disorders involving the presence of skin fibrosis and is
done through clinical and histopathological findings.
Systemic sclerosis affects the trunk and limbs,
similarly to NSF, but the face and neck are often affec-
ted. It is an autoimmune disease that involves the skin
and other organs and is most commonly seen in
women aged between 30 and 50 years. The American
College of Rheumatology requires the presence of
one major criterion (symmetric sclerosis proximal to
the metacarpophalangeal or metatarsophalangeal
joints) or two minor criteria (sclerodactyly, digital pit-
ting scars or loss of substance from the finger pad;
bibasilar pulmonary fibrosis). Telangiectasias and
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context of systemic sclerosis, such findings associated
with calcinosis, sclerodactyly, and esophageal dysmo-
tility constitute the CREST syndrome. Between 40 and
70% of the patients have anti-Scl-70 antibodies. The
presence of antinuclear antibodies, antineutrophil
cytoplasmic antibodies and antitopoisomerase antibo-
dies also facilitates the diagnosis of systemic sclerosis.
Thickened collagen bundles, vascular fibrosis, calcifi-
cation and mild lymphoplasmacytic inflammatory
infiltrate are observed by microscopy. The presence of
autoantibodies and histopathological features allow
the differential diagnosis. Patients with NSF do not
have anticentromere and anti-Scl-70 antibodies, there
is no facial involvement and associations with syste-
mic symptoms are distinct.42
Scleromyxedema is a rare condition usually
associated with monoclonal IgG-λ paraproteinemia,
which progresses to multiple myeloma in approxima-
tely 10% of the cases.2,42 It shows a distinct distribution
pattern, with involvement of the face and neck.
Patients with scleromyxedema show skin thickening
and hardening due to increased production of mucin,
collagen, fibroblast proliferation and dermal deposi-
tion of glycosaminoglycans.1 Unlike NSF, an inflamma-
tory infiltrate with a variable number of plasma cells is
observed.42 Skin changes are distributed in the upper
hemibody, initially in the face. Systemic involvement
occurs in all subtypes.
Lipodermatosclerosis shows skin changes res-
tricted to the lower limbs and is due to vascular stasis.
Joint contracture does not occur in this condition.
Graft versus host disease can be similar to NSF,
presenting with dyschromic fibrotic plaques, but with
typical involvement of the trunk. There is a history of
allogeneic transplant before the onset of symptoms.
The presence of numerous CD34-positive fibro-
blasts in some cases of NSF requires differential diag-
nosis with dermatofibrosarcoma protuberans
(DFSP). DFSP often presents with an extensive indu-
rated plaque due to involvement of the subcutaneous
tissue. It may occur above the neck facilitating diffe-
rentiation from NSF, and histopathology is essential
for diagnostic confirmation.
Eosinophilic fasciitis presents with sudden
onset of pain, swelling and erythema of the extremi-
ties with rapid progression. It evolves to cutaneous
sclerosis with contractures and restricted mobility wit-
hin months. It affects the forearms, arms, legs, thighs
and trunk; there is peripheral eosinophilia, increased
erythrocyte sedimentation rate and hypergammaglo-
bulinemia in most cases.42 Hyalinization and thicke-
ning of the collagen bundles of the deep fascia and
subcutaneous tissue, with clusters of eosinophils, are
also observed.
Metastatic calcifications, calciphylaxis, eosinophi-
lia-myalgia syndrome and porphyria cutanea tarda also
constitute the range of differential diagnoses of NSF.
Exclusive involvement of patients with renal
impairment, history of exposure to GBCA and typical
distribution of skin lesions of NSF favor the differen-
tial diagnosis.
TREATMENT
There is no specific treatment established. The
main objective in the management of patients with
NSF is recovery of the renal function, which relates to
delay of disease progression, regardless of the treat-
ment adopted.10 Spontaneous resolution of NSF in
renal transplant recipients has been reported.2
Nevertheless, lesions may remain unchanged after
renal transplantation, even if the transplanted organ
shows normal function.
The therapeutical approaches described are
anedoctal and include corticosteroids (topical and
systemic), topical vitamin D analogues, other immu-
nomodulators (methotrexate, thalidomide), vascular
compression stockings, extracorporeal photophere-
sis, plasmapheresis and chelates, among others.
The use of oral prednisone 1mg/kg/day shows
conflicting results.4,10 Its prolonged use may result in
significant adverse effects such as osteoporosis, poor
glycemic control in diabetics and increased risk of gas-
trointestinal ulceration. Pulses of methylprednisolone
followed by weekly methotrexate in a pediatric patient
yielded a good clinical outcome, but neutropenia pro-
ved to be a potentially fatal complication.13
Development of NSF in patients taking low doses of
prednisone has been described.8
The use of occlusive calcipotriol appears to be
of little value;3 however, the combination of calcipo-
triol with high-potency topical corticosteroids and vas-
cular compression stockings proved to be effective in
some cases.10,13
Patients with recent onset of the disease may
show improvement of skin lesions after treatment
with thalidomide (50 to 100 mg daily), which appa-
rently does not occur in patients with long-standing
disease.2,3 However, there are reports of the develop-
ment of NSF in patients who were already using thali-
domide to treat other comorbidities.10
Reduction of the fibrotic consistency of plaques
after extracorporeal photopheresis in patients diagno-
sed with NSF for less than one year has been descri-
bed, but patients who had been diagnosed with NSF
for a period longer than 12 months showed no res-
ponse to this therapy. None of the patients evaluated
showed improvement of renal function, which sug-
gests that the therapeutic benefit was exclusively due
to photopheresis.47 Because this treatment is safe and
relatively free of adverse effects, it should be conside-
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red in the initial management of NSF,12 but its use is
restricted by its high cost and limited availability.
Phototherapy with UVA and psoralens (PUVA),
associated or not with acitretin and prednisone, has
also proven to be effective for a limited number of
patients.10 Due to the potential reduction in collagen
synthesis secondary to the suppression of proinflam-
matory cytokines, photodynamic therapy, photophere-
sis and UVA phototherapy are promising alternatives.4
Plasmapheresis was also effective for 3 patients
who had undergone liver and kidney transplantation;
however, it is not known whether this satisfactory res-
ponse was due to improved renal function.3,10
High-dose intravenous immunoglobulin sho-
wed good results, as well as the use of intravenous
sodium thiosulfate in a restricted number of patients,
possibly due to their chelating and antioxidant pro-
perties.2-4,48
Pentoxifylline (1200mg daily) slowed the pro-
gression of and stabilized the disease due to its antifi-
brotic activity resulting from antagonism to tumor
necrosis factor alpha and from an increase in the flexi-
bility of red blood cells, which improves peripheral
circulation and reduces the incidence of thrombotic
events.16
Imatinib mesylate (Gleevec® - Novartis) inhibits
the synthesis of fibronectin and type I collagen by der-
mal fibroblasts in vitro. It may also reduce the synthe-
sis and accumulation of extracellular matrix as pre-
viously shown for bleomycin-induced dermal fibrosis.
Treatment of NSF patients with imatinib has been sho-
wing promising results.49 Persistent clinical and histo-
logic improvements were observed with the use of
400mg daily. The clinical benefits were maintained
regardless of Gd tissue deposition.50 The standard
duration of the treatment is yet to be determined
since skin abnormalities may recur after its interrup-
tion. Further studies are still necessary to better
understand imatinib’s role in the treatment of NSF
and other fibrotic conditions. 2,3,50,51 Cyclophos -
phamide did not show favorable results.4
Physiotherapy appears to be useful in preven-
ting and delaying the progression of joint restrictions,
as well as in restoring joint mobility. It should be pres-
cribed whenever possible. Better results were obtai-
ned with swimming.2,10,12
Even though recent reports show clinical
improvement of NSF after kidney transplantation,52
there are only few cases described and not all the
cases have shown benefits from this approach. To
date, kidney transplantation’s role in the management
of NSF still needs to be elucidated, lacking enough
evidence for further conclusions and recommenda-
tions. It should be noted that NSF itself does not con-
traindicate renal transplantation.
Reports of improvement with all treatment
options are anecdotal; thus, there are no specific
recommendations for the therapeutic management of
these patients so far.
PROGNOSIS
Improvement of renal function is associated
with that of skin lesions, which can resolve sponta-
neously following the restoration of normal renal
function. However, the disease is progressive in most
cases. So far there are no reports of spontaneous
regression of NSF not associated with improvement of
renal function. Despite the fact that improvement of
fibrotic symptoms is associated with improvement of
renal function, there are reports of development of
NSF in renal transplant patients after normalization of
renal function.
Cardiovascular diseases are the leading cause of
death in chronic terminal patients with renal impair-
ment with or without NSF. Increased mortality in
patients with terminal renal disease with NSF is repor-
ted compared with those who do not have the disea-
se. NSF does not directly cause death, but restrictions
caused by the fibrotic state may predispose to a lethal
outcome.2,10
Although not immediately life threatening, NSF
is a limiting condition with a major impact on quality
of life. It may result in joint contractures, reduced
mobility, and frequent falls and fractures. A multidisci-
plinary, integral approach is essential, as well as orien-
tation about the chronic and often progressive charac-
ter of the disease, for which there is no current effec-
tive treatment.
PREVENTION
The occurrence of NSF is closely related to the
exposure of patients with GFR < 30ml/min/1.73m2 to
GBCA. Due to the exclusive occurrence of the disease
in patients with renal impairment, non-use or cautious
use of GBCA in these individuals seems to be the only
preventive measure. An agent with preventive proper-
ties for use in patients at risk has not yet been descri-
bed. Patients with stages 4 and 5 CRI and severe acute
renal failure should not be exposed to GBCA. They
should also be avoided in the milder stages of renal
failure due to the progressive and debilitating nature
of the disease. Alternative imaging studies should be
prioritized.
The FDA and the American College of Radiology
recommend considering hemodialysis immediately
after or less than 2 hours after exposure to GBCA for
patients with stage 5 CRI and severe acute renal insuf-
ficiency (ARI), which is also acceptable for patients
already on peritoneal dialysis. In dialysis patients, it is
recommended to perform the test prior to dialysis, as
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well as suspend iron replacement a week before
MRI.53 Due to the high morbidity associated with the
placement of a large-caliber catheter for dialysis,
hemodialysis is not indicated for patients with stage 4
CRI. For these patients, the recommendation for tes-
ting must be accurate and the free consent form must
be signed.12 The performance of hemodialysis after
MRI removes approximately 75% of the contrast agent
present in a dialysis session and 95% of this agent
after three sessions. However, there are no studies
that prove the theoretical benefit of early dialysis.54
Repeated examinations should be avoided and any
contrast dose administered should be as small as pos-
sible. The use of a macrocyclic GBCA is preferred by
some authors in patients at increased risk in whom
contrast imaging cannot be avoided.
American and European recommendations for
the safe use of GBCA include: avoid use in patients
with severe renal impairment (give preference to
computed tomography with iodinated contrast
agents), in the perioperative period of liver transplan-
tation, in neonates and breastfeeding infants younger
than 4 months (due to their immature kidneys); use
the lowest recommended dose, avoid multiple expo-
sures to Gd; minimum interval of 1 week between
tests; track nephropathy prior to administration of
contrast; avoid use of linear chelating agents; consi-
der dialysis after contrast administration in patients
on renal replacement therapy. It is suggested that
patients on dialysis undergo 3 consecutive dialysis
sessions, the first within 2 hours after contrast expo-
sure; increase the number of dialysis bag exchanges
for patients on peritoneal dialysis and evaluate the
need for hemodialysis in these patients. There is no
evidence confirming that dialysis should be introdu-
ced to prevent or treat NSF in non-dialytic patients.26
CONCLUSION
NSF is a rare disease exclusive of patients with
renal impairment (acute or chronic) exposed to
GBCA, with a significant reduction of eGFR. Its phy-
siopathogenic mechanisms remain unclear but appear
closely related to the persistence of GBCA material in
the peripheral tissues of those at risk. No standard
treatment has been established. Similarly, the progno-
sis is still uncertain and responses to therapeutic
approaches are controversial. Preventing the establis-
hment of NSF appears to be the only certainty in this
enigmatic context.
The low incidence of NSF and the complexity of
affected patients are insurmountable obstacles to the
development of human controlled studies.
Experimental animal models have been proposed, but
there are still clinical-pathological discrepancies com-
pared to human cases.18
Cautious use of GBCA in patients with renal
disease has dramatically reduced the number of new
cases of NSF since the FDA’s initial warnings, in June
of 2006. Therefore, it is expected that with the restric-
tions on the use of these contrasts, especially in
patients with stages 4 and 5 CRI and severe ARI, NSF
will become a historical disease. q
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